Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT05614895
- Locations
- 🇺🇸
East Carolina University (ECU) Physicians - Infectious Disease Clinic - Greenville, Greenville, North Carolina, United States
🇺🇸Infectious Disease Associates, Sarasota, Florida, United States
🇰🇷Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1290
- Registration Number
- NCT05595642
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸AllerVie Clinical Research, Birmingham, Alabama, United States
🇺🇸Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT05583617
- Locations
- 🇫🇷
IGR, Villejuif, France
🇦🇺Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT05569148
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Retinal Consultants of Arizona, Phoenix, Arizona, United States
A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT05562947
- Locations
- 🇨🇳
Sichuan Provincial People's Hospital, Chengdu, China
🇨🇳Shanxi Eye Hospital, Taiyuan, China
🇨🇳Central Theater General Hospital of the Chinese People's Liberation Army, Wuhan, China
A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
- Conditions
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT05548556
- Locations
- 🇮🇹
Policlinico Universitario Agostino Gemelli; UOC Neurologia, Roma, Lazio, Italy
🇮🇹ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Centro clinico NEMO (NEuroMuscular Omnicentre), Milano, Lombardia, Italy
🇺🇸Virginia Commonwealth University Medical Center; Department of Neurology, Richmond, Virginia, United States
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT05535244
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT05533775
- Locations
- 🇧🇷
Hospital Erasto Gaertner, Curitiba, Brazil
🇧🇷GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, Sao Paulo, Brazil
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
- Conditions
- Interventions
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT05503264
- Locations
- 🇫🇷
Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris, France
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸UC San Diego; ACTRI, La Jolla, California, United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
- Conditions
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05494619